A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

Clinical and Experimental Immunology

Volumn 106, Issue 3, 1996, Pages 427-433

  Isaacs, J D ^a,c   Wing, M G ^a   Greenwood, J D ^a   Hazleman, B L ^b   Hale, G ^a   Waldmann, H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Rheumatology and Rehabilitation Research Unit   (United Kingdom)

Author keywords

Campath; Cytokine; Fc receptors; Monoclonal antibody; Rheumatoid arthritis

Indexed keywords

ALEMTUZUMAB; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029852737     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-876.x     Document Type: Article

References (35)

1. Isaacs JD, Manna VK, Rapson N et al. CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Brit J Rheumatol 1996; 35:231-40.
2. Isaacs JD. Monoclonal antibodies in rheumatology. In: Ritter M, Ladyman P, eds. Monoclonal antibodies: production, engineering and clinical application. Cambridge: Cambridge University Press, 1985:403-28.
3. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166:1351-61.
4. Bindon CI, Hale G, Bruggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as Clq. J Exp Med 1988; 168:127-42.
5. Alters SE, Sakai K, Steinman L, Oi V. Mechanisms of anti-CD4-mediated depletion and immunotherapy: a study using a set of chimeric anti-CD4 antibodies. J Immunol 1990; 144:4587-92.
6. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993; 23: 1098-104.
7. Isaacs JD, Clark MR, Greenwood J, Waldmann H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 1992; 148:3062-71.
8. Powelson JA, Knowles RW, Delmonico FL, Kawai T, Mourad G, Preffer FK, Colvin RB, Cosimi RB. CDR-grafted OKT4A monoclonal antibody in cynomolgous renal allograft recipients. Transplantation 1994; 57:788-93.
9. Hale G, Xia M-Q, Tighe HP, Dyer MJS, Waldmann H. The Campath-1 antigen (CDw52). Tissue Antigens 1990; 35:118-27.
10. Reichmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7.
11. Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73:1431-9.
12. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H. Humanised monoclonal antibody for rheumatoid arthritis. Lancet 1992; 340:748-52.
13. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341:1620-2.
14. Moreault T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344:298-301.
15. Watts RA, Isaacs JD, Hale G, Hazleman BL, Waldmann H. Peripheral blood lymphocyte subsets after CAMPATH-1H therapy in rheumatoid arthritis-a 3 year follow-up. Arthritis Rheum 1994; 37:S338.
16. Weinblatt ME, Maddison PJ, Bulpitt KJ et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum 1995; 38:1589-94.
17. Cobbold SP, Qin S, Leong LYW, Martin G, Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 1992; 129: 165-201.
18. Chatenoud L, Bach J-F. OKT3 in allogeneic transplantation: clinical efficacy, mode of action, and side effects. In: Burlingham WJ, ed. A critical analysis of monoclonal antibody therapy in transplantation. Boca Raton: CRC Press, 1992.
19. Moreault T, Coles A, Wing MG, Isaacs J, Hale G, Waldmann H. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119:225-37.
20. German SD, Clark MR. Humanisation of monoclonal antibodies for therapy. Seminars Immunol 1990; 2:457-66.
21. Page MJ, Sydenham M. High level expression of the humanised monoclonal antibody CAMPATH-1H in Chinese hamster ovary cells. Biotechnology 1990; 9:64-68.
22. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarrington GT. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable marker. Biotechnology 1992; 10:169-75.
23. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
24. Cobbold SP, Rebello PRUB, Davies HFfS, Friend PJ, Clark MR. A simple method for measuring patient antiglobulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990; 127: 19-24.
25. Hale G, Clark M. Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134:3056-61.
26. Van de Winkel JGJ, Anderson C. Biology of human immunoglobulin G Fc receptors. J Leukocyte Biol 1991; 49:511 24.
27. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403-11.
28. Matteson EL, Yocum DE, St Clair EW et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily sub-cutaneous injection. Arthritis Rheum 1995; 38:1187-93.
29. + effector cells by rheumatoid factor complex. Role of natural killer cells in rheumatoid arthritis. Arthritis Rheum 1991; 34:423-31.
30. Ravetch JV, Kinet J-P. Fc receptors. Ann Rev Immunol 1991; 9:457-92.
31. Ucker DS, Hebshi LD, Blomquist JF, Torbett TE. Physiological T-cell death: susceptibility is modulated by activation, aging and transformation, but the mechanism is constant. Immunol Rev 1994; 142: 273-99.
32. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988; 18:1507-14.
33. Garred P, Michaelsen TE, Aase A. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 1989; 30:379-82.
34. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991; 21: 11-16.
35. Isaacs J, Greenwood J, Waldmann H. An in vivo model for determining rules of antibody design. J Cell Biochem 1994; Suppl. 18D:206.